Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of SHR-8068 with adebrelimab and bevacizumab in advanced hepatocellular carcinoma
CTR20221602Phase 2Active
- Sponsor
- Chengdu Shengdi
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CS1002, adebrelimab and bevacizumab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Chengdu Shengdi. Primary endpoints: Dose-limiting toxicity, Grade 3 or higher treatment-related adverse events and serious treatment-related serious adverse events with dual combination and 2 more. Started Aug 2022; status: active.
02
Drugs
CS1002adebrelimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221602.